-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 11, Langyu Pharmaceutical Technology (Hangzhou) Co.
, Ltd.
(hereinafter referred to as "Langyu Pharmaceutical") announced the official launch of Phase II clinical trials of Cavosonstat (N91115), a new class I drug developed by it for the treatment of moderate to severe asthma
.
Among them, the United States has cooperated with the precise institution funded by the National Institutes of Health (NIH).
Asthma has become one of the most common diseases in the world today
.
According to the Global Initiative for Asthma Prevention and Control (GINA), there are about 300 million people suffering from asthma in the world; according to WHO's forecast, the number of asthma patients will increase to 400 million by 2025
Among the anti-inflammatory drugs currently on the market, inhaled corticosteroids are the mainstay and a small amount of interleukin inhibitors are injected
Note: The original text has been deleted